UK Puberty Blocker Trial Sets Minimum Age of 11 Amid Safety Overhaul

UK Clinical Trial for Puberty Blockers Moves Forward With Stricter Safeguards

Gender-questioning children in the United Kingdom will need to be at least 11 years old to participate in a closely watched clinical trial designed to evaluate the safety and effectiveness of puberty-blocking drugs. The updated age requirement is among several new protective measures introduced following concerns raised by the country's medicines regulator.

Trial Paused and Revised After Regulatory Concerns

The study, known as the Pathways Trial, was placed on hold in February 2026 after the Medicines and Healthcare products Regulatory Agency (MHRA) flagged safety concerns and initially recommended raising the minimum participation age to 14. Following detailed discussions between the MHRA and the research team, a compromise was reached, lowering that threshold while implementing a broader range of enhanced safeguards.

The revised protocol now sets the minimum age at 11 for participants registered female at birth, and 12 for those registered male at birth. Researchers from King's College London, who are leading the study, have committed to holding off on recruiting participants until after 1 August, allowing time for current legal proceedings to run their course.

What the Trial Involves

Originally approved by UK regulators and ethics committees in November 2025, the Pathways Trial is designed to enroll children under the age of 16 who are experiencing gender-related distress and are already accessing gender healthcare services. The study aims to assess how puberty-suppressing hormones (PSH) affect participants across physical, social, and emotional dimensions.

Puberty blockers — medications that delay or halt the onset of puberty — were banned in the UK for anyone under 18 in 2024, following a landmark review by Dr. Hilary Cass. That review concluded that the evidence base underpinning gender medicine had been built on "shaky foundations." Since then, access to these treatments has been heavily restricted, leaving many young people without options.

Additional Protections Put in Place

Alongside the new age thresholds, several other safeguards have been strengthened. No child will be permitted to enroll without explicit parental consent, and all participants must demonstrate a clear and thorough understanding of the treatment, including its potential benefits and associated risks.

Clearer clinical guidelines are also being introduced regarding when the drugs should be discontinued. These include situations where concerns arise over bone density, cognitive function, or unexpected physical symptoms such as vaginal bleeding. Participants will also receive more comprehensive information about options for preserving their fertility — a key concern raised by critics of the trial.

Researchers emphasized that while patient information and age criteria have been reinforced, there are "no major changes to the overall design or conduct" of the trial itself.

Legal Challenges Cloud the Timeline

Despite these updates, the trial faces significant legal opposition. A number of clinicians and advocacy groups are challenging the trial's ethical foundations and safety standards in court. They argue that children are incapable of providing truly informed consent for a treatment that may have lasting implications for their fertility and long-term health.

Professor Sir Jonathan Montgomery, a Professor of Health Care Law at University College London, acknowledged the value of this legal scrutiny, stating that if regulators had overlooked any legal issues, "it is in everyone's interests that these are clarified as soon as possible." He noted that the proceedings are expected to provide an additional layer of oversight for the trial.

Experts and Advocates Weigh In

Dr. Hilary Cass, whose 2024 review triggered the original ban on puberty blockers for under-18s, has since spoken publicly in favor of the trial proceeding. She warned the BBC that without rigorous clinical research, vulnerable young people risk being exploited by unregulated providers — particularly those selling the drugs privately online. She described the trial as "vital" to preventing what she called "ongoing charlatans just handing out inappropriate drugs."

Meanwhile, LGBTQ+ charity Stonewall expressed cautious optimism about the revised protocol. A spokesperson for the organization welcomed the agreement, noting that thousands of young people have been "left in limbo" since the 2024 ban. The spokesperson said the situation had caused significant "emotional and physical distress" and stressed that "no-one wants to see that distress further prolonged."

Looking Ahead

The first participants are tentatively expected to be recruited in August, though the timeline remains subject to the outcome of ongoing legal proceedings. The Pathways Trial represents one of the most consequential and contested pieces of medical research currently underway in the UK, sitting at the intersection of medicine, ethics, child welfare, and public debate over gender healthcare.